Invictus MD Investor Dashboard

Company Overview:

Invictus has partnered with business leaders to convey our corporate vision, including KISS music legend and business mogul Gene Simmons as our Chief Evangelist Officer. To meet growing demand, Invictus is expanding its cultivation footprint, with three cannabis production facilities licensed under the Cannabis Act and Cannabis Regulations in Canada. To accommodate international sales, Invictus’ wholly-owned subsidiary, Acreage Pharms Ltd., has designed and is currently in the final stages of building its Phase 3 purpose-built cultivation facility to be European Union Good Manufacturing Practices compliant. The Company is targeting up to 50 percent of production to medical cannabis. To ensure consistency in quality and supply, Invictus maintains all aspects of the growing process through its subsidiary, Future Harvest Development Ltd., a high-quality fertilizer and nutrients manufacturer. Invictus drives sustainable long-term shareholder value through a diversified product portfolio with over 70 Health Canada approved strains and a multifaceted distribution strategy including medical, adult-use, international, Licensed Producer to Licensed Producer and retail stores.

[stock_market_chart symbol=”GENE.V” range=”1y” settings='{“primaryChartType”:”smoothedLine”,”width”:”100%”,”height”:”350px”,”marginTop”:0,”marginBottom”:0,”marginLeft”:10,”marginRight”:10,”primaryPanelTitle”:”Price”,”secondaryPanelTitle”:”Volume”,”fontSize”:13,”color”:”#383838″,”primaryLineColor”:”#000″,”primaryLineColorAlpha”:0.15,”secondaryLineColor”:”#000″,”secondaryLineColorAlpha”:0.15,”backgroundColor”:”#fff”,”gridColor”:”#e0e0e0″,”gridAlpha”:0.8,”cursorColor”:”#ba0000″,”cursorAlpha”:0.8,”scrollbarBackgroundColor”:”#fff”,”scrollbarSelectedBackgroundColor”:”#000″,”scrollbarGraphFillColor”:”#000″,”scrollbarSelectedGraphFillColor”:”#000″,”primaryLineThickness”:0,”secondaryLineThickness”:0,”gridThickness”:0,”precision”:2,”thousandsSeparator”:”,”,”decimalSeparator”:”.”,”usePrefixes”:false,”mouseWheelZoomEnabled”:false,”cursorEnabled”:false,”exportEnabled”:false,”scrollbarEnabled”:false,”legendEnabled”:false,”periods”:”1W,1M,6M,YTD,1Y,ALL”,”defaultPeriod”:”1y”}’]

Key Share Information:

Key Balance Sheet Information (in Millions $CAD):

	CYQ1'17	CYQ2'17	CYQ3'17	CYQ4'17	CYQ1'18	CYQ2'18	CYQ3'18	CYQ4'18	CYQ1'19
Cash	0.46	4.41	28.63	26.33	37.59	19.45	10.67	23.77	9.83
Biological Assets				0.26	0.18	0.15	0.06	0.24	0.31
Inventory	0.55	0.64	0.65	1.19	2.30	2.68	2.96	2.61	3.28
Total Assets	20.05	76.96	92.78	92.37	115.45	118.53	117.36	144.74	153.91
Net Tangible Assets	18.89	24.06	47.31	46.74	60.82	55.71	56.90	83.66	86.03
Intangibles/Goodwill	1.16	52.90	45.47	45.63	54.63	62.83	60.46	61.08	67.87
Total Liabilities	2.42	1.29	0.54	11.15	12.61	11.59	13.78	23.94	36.74

Key Operating Items (Quarterly in Millions $CAD):

	CYQ1'17	CYQ2'17	CYQ3'17	CYQ4'17	CYQ1'18	CYQ2'18	CYQ3'18	CYQ4'18	CYQ1'19
Revenue	$2.55	$0.49	$0.57	$0.62	$2.36	$1.30	$0.46	$1.74	$4.69
Change in Fair Value of Biologial Assets				$0.70	$1.31	$0.34	-$0.02	-0.40	1.61
Gross Margin	$0.99	$0.06	$0.09	$1.04	$1.66	$0.56	$0.16	0.53	1.51
Marketing and Sales	$0.50	$0.69	$0.83	$0.36	$2.75	$0.99	$1.49	5.63	14.45
Investor Relations	$0.02		$0.01
Total Operating Expenses	$6.33	$6.22	$2.54	$2.61	$20.70	$3.47	$6.33	11.26	33.30
Operating Cash Flow (Quarterly)	-$2.50		-$2.36	-$3.72	-$0.19		-$4.61	-2.54	-7.53
Investing Cash Flow (Quarterly)	-$8.83		-$2.04	-$0.44	$0.59		-$8.03	-14.33	-12.87
Financing Cash Flow (Quarterly)	$11.56		$25.62	$1.86	$13.87		$3.86	29.98	6.45

Listing Statement